Close
Achema middle east
swop processing & packaging

GenScript ProBio and RVAC Medicines Announce Strategic Partnership for GMP Plasmid DNA Manufacturing for mRNA COVID-19 Vaccine Candidate

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

ACHEMA 2027: Global Forum for Pharma and Life Sciences

ACHEMA 2027 sets an even stronger focus on innovations...

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

GenScript ProBio, a leading global Contract Development and Manufacturing Organization (CDMO), and RVAC Medicines Pte. Ltd., a biotechnology company focusing on the development and commercialization of  messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement to establish a strategic partnership for the manufacturing of GMP-grade plasmid DNA (pDNA) for its mRNA COVID-19 vaccine candidate, RVM-V001, along with collaboration for future therapeutic pipelines.

GenScript ProBio will provide GMP plasmid manufacturing service for RVAC Medicines’ program, RVM-V001. This partnership will enable to accelerate its clinical manufacturing of mRNA-based COVID-19 vaccine, RVM-V001, and future mRNA-based vaccines targeting infectious diseases such as Respiratory syncytial virus (RSV) and Clostriodioides difficile infection (CDI).

Dr. Brian Min, CEO of GenScript ProBio said, “We are delighted to enter into this strategic partnership with RVAC Medicines. This collaboration will enable us to utilize our cutting-edge GMP plasmid manufacturing platform technology to support the development of mRNA-based COVID-19 vaccine and its therapeutic candidates.”

Dr. Sean Fu, CEO of RVAC Medicines said, “We are excited to work closely with GenScript ProBio. With its technical strength and customer centric approach, GenScript ProBio will help to accelerate the development of RVAC’s pipeline.”

As RVAC advances the development of its mRNA candidates, GenScript ProBio continues to provide high-quality GMP materials critical to the mission, including plasmid DNA and the development of ancillary materials to support mRNA manufacturing process. In addition to the manufacturing of plasmid DNA, the GenScript ProBio team provides consultative and expert guidance regarding quality and regulatory expectations of agencies worldwide.

RVAC Medicines will continue to collaborate with GenScript ProBio to support its mRNA initiatives for both clinical-stage development and commercial stage.

Latest stories

Related stories

ACHEMA 2027: Global Forum for Pharma and Life Sciences

ACHEMA 2027 sets an even stronger focus on innovations...

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »